Current Status of Checkpoint Inhibitors in the Treatment of Esophageal and Gastric Tumors - Overview of Studies

Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
David VránaB Melichar

Abstract

Despite recent advances in oncological treatment, gastric and esophageal cancer remain neoplastic diseases with poor prognoses. The only potential curative treatment is surgical resection with adjuvant or neoadjuvant chemotherapy/chemoradiotherapy. Targeted therapy of metastatic disease unfortunately does not provide better outcomes than for other tumor types, with the exception of trastuzumab and ramucirumab, which have relatively limited efficacy. Immunotherapy is a rapidly evolving treatment that has influenced the treatment guidelines for many tumors. In the present review, we summarize clinical trials of checkpoint inhibitors for the treatment of gastric and esophageal cancer, including published results and the perspectives of ongoing trials. Gastric and esophageal cancer are tumors with high mutation loads that have attracted considerable attention since the beginning of interest in immunotherapy. Phase I clinical trials (Keynote 012, Javelin, KEYNOTE 028) have demonstrated efficacy and acceptable toxicity. These studies were followed by phase II clinical trials (KEYNOTE 059, CheckMate 032, JapicCTI-No.142422), which showed about a 10-30% overall tumor response rate and confirmed the predictive role of PD-L1 expression. ...Continue Reading

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
B Melichar, M Spisarová
Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
Tomáš Pokrivčák, Alexandr Poprach
Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
I Krajsová
Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
O BílekL Zdražilová-Dubská
Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
R Obermannova
© 2022 Meta ULC. All rights reserved